PeerVoice Oncology & Haematology Video
By PeerVoice
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by PeerVoice
Category: Science
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 9
Reviews: 0
Episodes: 195
Description
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
| Episode | Date |
|---|---|
|
Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice
|
May 30, 2025 |
|
Giada Sebastiani, MD, FAASLD - Shedding Light on the Detection and Management of MASLD/MASH: Expert Insights to Improve Outcomes
|
May 30, 2025 |
|
Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls
|
May 30, 2025 |
|
Chloe E. Atreya, MD, PhD / Marwan Fakih, MD - Focusing on the Patient in Front of Us: Expert Perspectives on Providing Patient-Centered Care for Refractory Metastatic Colorectal Cancer
|
May 16, 2025 |
|
Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy
|
May 08, 2025 |
|
Krista Noonan, BSc, MD, FRCPC / Elizabeth R. Plimack, MD, MS, FASCO - Redefining the Standards of Care in RCC: Expert Insights to Translate Recent Advances to Clinical Practice
|
May 08, 2025 |
|
Dustin A. Deming, MD - Personalizing Treatment Pathways for Refractory Metastatic Colorectal Cancer: Informed Decision-Making When Disease Has Progressed
|
Apr 21, 2025 |
|
Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer
|
Apr 21, 2025 |
|
Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care
|
Apr 02, 2025 |
|
Enrico Lopriore, MD, PhD - Are You Managing Pregnant Individuals? Then You Need to Know About Fetal-Neonatal Alloimmune Thrombocytopenia (FNAIT)
|
Mar 26, 2025 |
|
Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?
|
Mar 26, 2025 |
|
Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma
|
Mar 19, 2025 |
|
Kim Ma, MD - Addressing Unmet Needs in ER+, HER- Advanced Breast Cancer: The Evolution of Endocrine Therapy
|
Mar 19, 2025 |
|
Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment
|
Mar 12, 2025 |
|
Claire Harrison, DM, FRCP, FRCPath - Patient-Centred Care in Cytopenic Myelofibrosis: Collaborative Conversations on Treatment Goals and Decisions
|
Mar 05, 2025 |
|
Rachel Goodwin, MD, MSc, FRCPC - Improving Care for Advanced Colorectal Cancer With Later-Line Treatments
|
Jan 13, 2025 |
|
Dirk Arnold, MD, PhD - Still in the Game! Optimising Treatment Sequencing in the Management of Relapsed or Refractory mCRC
|
Dec 27, 2024 |
|
Michael K. Wong, MD, PhD, FRCPC - When Anti-PD1 Therapy Fails: Could Oncolytic Immunotherapy Impact Outcomes in Advanced Melanoma?
|
Dec 13, 2024 |
|
Srikala Sridhar, MD, MSc, FRCPC - Transforming Care With Immunotherapy Combinations in the First-Line Treatment of Advanced or Metastatic Urothelial Carcinoma
|
Dec 13, 2024 |
|
Linda Lee, MD, FRCPC / Jacob Rullo, MD, PhD, FRCSC - Managing MEK-Inhibitor–Associated Retinopathy in Metastatic Melanoma: An Expert Discussion
|
Dec 13, 2024 |
|
Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer
|
Dec 12, 2024 |
|
Versha Banerji, MD, FRCPC - Raising the Bar: The Evolving Role of BTK Inhibitors in CLL Management
|
Dec 12, 2024 |
|
John Mascarenhas, MD - Working With Our Patients as Partners in Care: Addressing Disease- and Treatment-Related Burdens Associated With Cytopenic Myelofibrosis
|
Nov 21, 2024 |
|
Paul Wheatley-Price, BSc, MBChB, MD, FRCP (UK) / Parneet K. Cheema, MD - Addressing Key Challenges to Improve Outcomes in Patients With NSCLC With Rare Actionable Genomic Alterations
|
Nov 21, 2024 |
|
Harry Paul Erba, MD, PhD - New Tools, New Considerations: Optimizing Our Approaches to Managing Newly Diagnosed FLT3-Mutant AML
|
Nov 15, 2024 |
|
Maurie Markman, MD - Testing Impacts Treatment: Applying Best Practices in HER2 Assessment in Solid Tumours
|
Nov 15, 2024 |
|
Neal Shore, MD, FAC - Advancing Care for mCRPC With Life-Prolonging Therapies: Existing and Emerging Roles for Radiopharmaceuticals
|
Nov 08, 2024 |
|
Richard Kim, MD - The Modern Art of Sequencing Later Lines of Treatment for Advanced Colorectal Cancer: Exploring Case Scenarios With the Experts
|
Nov 08, 2024 |
|
Ffion Davies, MBChB, FRCPCH, FRCEM - Managing Major Bleeding in Patients Receiving DOACs: Data, Developments, and Decision-Making in the ED
|
Nov 08, 2024 |
|
Ana Oaknin, MD, PhD - HER2 as an Actionable Target in Gynaecological Cancers: Implications of Therapeutic Advances on Clinical Practice
|
Nov 08, 2024 |
|
Karin Jordan, MD, PhD - Applying Foresight to Optimise Emesis Control in Patients Receiving Antibody-Drug Conjugates
|
Oct 25, 2024 |
|
Elena Castro, MD, PhD - Innovation and Individualisation in mHSPC and nmCRPC: Optimising Patient Outcomes and Experiences
|
Oct 25, 2024 |
|
Karin Jordan, MD, PhD - Practical Protocols for Preventing and Managing Antibody-Drug Conjugate-Associated Nausea and Vomiting
|
Oct 11, 2024 |
|
Peter Schmid, FRCP, MD, PhD - Staying at the Forefront of HER2 and TROP2-Directed Antibody-Drug Conjugate Advances in Breast Cancer
|
Oct 11, 2024 |
|
Simron Singh, MD, MPH - Addressing the Challenges of Treating Highly Proliferative Neuroendocrine Tumours: Review of the Latest Evidence
|
Sep 30, 2024 |
|
Andrea Necchi, MD - Practical Considerations for ADC-ICI Combinations in Advanced Urothelial Carcinoma: Identifying and Managing Adverse Events
|
Sep 30, 2024 |
|
Christine Brezden-Masley, MD, PhD, FRCPC - Breaking Barriers: Expert Guidance on Best Strategies for Biomarker Testing in Gastric and GEJ Cancers
|
Sep 30, 2024 |
|
Diana N. Ionescu, MD - Pathological Assessment of HER2 Status in Gastric and Gastroesophageal Cancers: Important Steps That Can Impact Outcomes
|
Sep 30, 2024 |
|
Alon Altman, MD, FRCSC - Upping the Ante in Advanced Endometrial Cancer Care: Optimizing the Use of Immunotherapy to Improve Patient Outcomes
|
Sep 23, 2024 |
|
Elizabeth Smyth, MD, FRCP - When They Need More Than Trastuzumab: Deciding on What’s Next for Patients With HER2+ Gastric Cancer
|
Sep 23, 2024 |
|
Stephanie Snow, MD, FRCPC - Mastering HER2 in GI Malignancies: Immunotherapy and Chemotherapy Backbones for Optimal Patients Outcomes
|
Sep 12, 2024 |
|
Christine Brezden-Masley, MD, PhD, FRCPC - Navigating HER2+ Early Breast Cancer Care: A Multidisciplinary Roadmap to Better Survival
|
Sep 12, 2024 |
|
Jacqueline S. Garcia, MD - Small Words, Big Differences: Best Practices in Supportive Care for Patients With AML
|
Aug 22, 2024 |
|
Brandon Blue, MD - Challenging Racial Disparities in Multiple Myeloma Treatment and Outcomes: Local Solutions to Address an Endemic Problem
|
Aug 22, 2024 |
|
Teresa Tiano, Honours B.A. - A Challenging Journey: A Patient-Centred Perspective on Gastric Cancer
|
Aug 22, 2024 |
|
Richard Kim, MD - From Trial Protocol to Routine Practice: Evaluating Real-World Evidence for Later-Line Treatments in Advanced Colorectal Cancer
|
Aug 22, 2024 |
|
Ravi Ramjeesingh, MD, PhD, FRCPC - Immunotherapy for Biliary Tract Cancers: Changing the Narrative in Rare and Aggressive Tumours
|
Aug 12, 2024 |
|
Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy
|
Aug 02, 2024 |
|
Philippe Moreau, MD - Assessing Current and Potential Approaches in Multiple Myeloma: Updates From Madrid 2024
|
Aug 02, 2024 |
|
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
|
Aug 02, 2024 |
|
Andrea Necchi, MD - Familiar Tools, New Uses? Assessing Novel Combination Approaches in the First-Line Management of Advanced Urothelial Carcinoma
|
Jul 22, 2024 |
|
Shaji Kumar, MD - Age Is More Than Just a Number: Tailoring Treatment Across the Multiple Myeloma Journey for Our Older and/or Unfit Patients
|
Jul 22, 2024 |
|
María-Victoria Mateos, MD, PhD - Updates in Multiple Myeloma From Madrid: Data Surrounding BCMA-Directed Agents and Their Clinical Relevance
|
Jul 22, 2024 |
|
David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey
|
Jul 22, 2024 |
|
Jonathan W. Riess, MD, MS - The Central Role of the Pathologist in Detecting MET Alterations: Enabling Multidisciplinary Teams to Do More With Less in NSCLC
|
Jun 03, 2024 |
|
Jeffrey Habert, MD, CCFP, FCFP - Steps Towards Earlier Detection of Lung Cancer: Harnessing the Power of Primary Care
|
May 30, 2024 |
|
Mohamed El-Hussein, RN, PhD, NP / Caitlin Carreau, MN, RN(EC) - At the Forefront of Cancer Prevention: Nursing Strategies to Optimize HPV Immunization
|
May 30, 2024 |
|
Lindsey Roeker, MD - Differentiating Between BTK Inhibitors in CLL: Same Class, Distinctly Dissimilar Agents
|
May 21, 2024 |
|
Thomas Powles, MBBS, MRCP, MD - Optimising Outcomes for Our Patients With Advanced Urothelial Carcinoma: Best Practices and Future Directions in Maintenance Therapy
|
May 10, 2024 |
|
Sara Hurvitz, MD - A New Jigsaw Piece for Our Patient’s Puzzle: TROP2-Directed Therapy in HR+ Advanced Breast Cancer
|
May 10, 2024 |
|
Jeffrey Szer, MBBS, FRACP - The Quest for Optimal Haemolytic Control of Paroxysmal Nocturnal Haemoglobinuria
|
Apr 17, 2024 |
|
Abdulazeez Salawu, MBBS, MSc, PhD - The Case for Biomarker-Guided Management of mCRC: Steps to Refine Care Along the Patient’s Journey
|
Apr 17, 2024 |
|
Dirk Arnold, MD - Navigating Decisions With Limited Tools: A Review of Best Practices in Managing Metastatic Colorectal Cancer
|
Apr 10, 2024 |
|
Lisa Licitra, MD - Are You Forearmed When Managing Toxicities Associated With Chemoradiotherapy in Patients With SCCHN?
|
Mar 28, 2024 |
|
Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
|
Mar 26, 2024 |
|
Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes
|
Mar 11, 2024 |
|
Matthew Kang, MD, FRCPC - Putting the Individual in ITP: Enhancing Patients Outcomes With TPO-RAs
|
Mar 06, 2024 |
|
George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action
|
Feb 28, 2024 |
|
Geoffrey Liu, MD, MSc, FRCPC, FISPE - Optimizing the Potential for Patients With ALK-Positive mNSCLC Throughout Their Treatment Journey
|
Feb 27, 2024 |
|
Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line
|
Feb 27, 2024 |
|
Paul Wheatley-Price, MBChB, MD - The Track to Better Outcomes: Identifying and Managing Patients With NTRK-Positive Solid Tumours
|
Feb 23, 2024 |
|
Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey
|
Feb 13, 2024 |
|
Michael Chu, MD - A Smooth Ride: How to Optimize the Patient Journey With CAR T-Cell Therapy in Multiple Myeloma
|
Feb 12, 2024 |
|
Shawn Malone, MD, FRCPC - Maximizing Survival in mCRPC: Case-Based Guidance to Optimize Sequencing Decisions
|
Feb 12, 2024 |
|
Donna E. Reece, MD - Cases in Relapsed Refractory Multiple Myeloma: The Role of Anti-CD38–Based Regimens in an Evolving Canadian Landscape
|
Feb 07, 2024 |
|
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
|
Feb 01, 2024 |
|
Ana C. Garrido-Castro, MD / Sarah L. Sammons, MD - TROP2-Directed Antibody-Drug Conjugates for Breast Cancer: The Clinical Significance of the Construct
|
Jan 25, 2024 |
|
Normand Blais, MD - Adjuvant Immunotherapy in Patients With Solid Tumours: Addressing Challenges With System Capacity in the Canadian Healthcare Setting
|
Jan 24, 2024 |
|
Eric Legius, MD, PhD - Building Blocks for Better Management of NF-1–Associated Plexiform Neurofibromas: Integrating New Evidence Into Canadian Clinical Practice
|
Jan 12, 2024 |
|
Elena Castro, MD, PhD - Radioligand Therapy and Therapeutic Sequencing in mCRPC
|
Jan 03, 2024 |
|
Brandon Sheffield, MD, FRCPC - Identifying Actionable Targets in Solid Tumours: The Importance of Comprehensive Genomic Profiling
|
Jan 03, 2024 |
|
Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations
|
Dec 28, 2023 |
|
Christine Simmons, MD, MSc, FRCPC - Managing HR+/HER2- Metastatic Breast Cancer in the Community: Optimizing Safety to Maximize Benefit
|
Dec 28, 2023 |
|
Steven Mark Taylor, MD, FRCS(C), FACS - Beyond Face Value: The Case for Considering Immunotherapy in Locally Advanced cSCC
|
Dec 28, 2023 |
|
Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape
|
Dec 28, 2023 |
|
Angela Lamarca, MD, PhD, MSc - Overcoming Barriers to Better Care in CCA: Keys to Optimising Multidisciplinary Care, Molecular Testing, and Targeted Treatment
|
Dec 19, 2023 |
|
Karim Fizazi, MD, PhD - Radioligand Therapy for Prostate Cancer: Predicting Who May Benefit and Who May Not
|
Dec 19, 2023 |
|
Ken Herrmann, MD, MBA - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
|
Dec 11, 2023 |
|
Brian I. Rini, MD, FASCO - Doubling and Tripling Up: Maximizing Outcomes With Combination Therapies in Renal Cell Carcinoma
|
Dec 11, 2023 |
|
Aly-Khan A. Lalani, BSc(Hons), MD, FRCPC - Tailoring Immunotherapy-Based Combination Treatment in Advanced RCC: Key Updates to Refine Care
|
Dec 01, 2023 |
|
Aditya Bardia, MD, MPH - When HER2 Is Low or Negative: Emerging Evidence on Antibody-Drug Conjugates for Hormone Receptor-Positive and Triple-Negative Breast Cancers
|
Dec 01, 2023 |
|
Karim Fizazi, MD, PhD - The Science and the Art of Modern Prostate Cancer Care: Improving Patient Outcomes Through Intensification and Individualisation of Treatment
|
Nov 16, 2023 |
|
Richard LeBlanc, MD - BCMA-Targeted Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: Why, Who, and When
|
Oct 30, 2023 |
|
Lorenza Rimassa, MD - When One Size Doesn’t Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma
|
Oct 24, 2023 |
|
Mita Manna, MD, FRCPC - CDK4/6 Inhibitors in HR+/HER2- High-Risk Early Breast Cancer: Considerations in Care
|
Oct 05, 2023 |
|
Kim N. Chi, MD, FRCPC / Steven Yip, MD, MSc, FRCPC - Personalizing Treatment Selection, Sequencing, and Future Opportunities for Patients With Advanced Prostate Cancer
|
Oct 05, 2023 |
|
David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting
|
Sep 29, 2023 |
|
Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?
|
Sep 29, 2023 |
|
Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?
|
Sep 26, 2023 |
|
Amit Singal, MD, MS - Recognising the Rationale and Understanding the Outcomes for CTLA-4 Targeted Therapies in Advanced HCC
|
Sep 19, 2023 |
|
Anna Tinker, MD, FRCPC - Maximizing Survival in Advanced or Recurrent Endometrial Cancer: The Evolving Role of Immunotherapy
|
Sep 19, 2023 |
|
David Malka, MD, PhD - Let’s Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma
|
Sep 14, 2023 |
|
Frank Siebenhaar, MD - Indolent Isn’t Insignificant: Raising Awareness of Systemic Mastocytosis and Its Symptoms
|
Sep 14, 2023 |
|
Julie Stakiw, MD, FRCPC - Frailty Assessment and Improved Care in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients
|
Sep 13, 2023 |
|
Barbara Melosky, MD, FRCPC - Narrowing the Care Gap in NSCLC With Rare EGFR Alterations: The Next Frontier in Precision Medicine
|
Sep 08, 2023 |
|
Stephen Chia, MD, FRCP(C) - Keeping Abreast of the Latest Advances in HER2-Positive Metastatic Breast Cancer Treatment: Clinical Implications for the Canadian Landscape
|
Sep 05, 2023 |
|
Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise
|
Jul 31, 2023 |
|
Javier Cortés, MD, PhD - Updates on HER3-Targeted Therapies in NSCLC and Breast Cancer
|
Jul 24, 2023 |
|
Joe O'Sullivan, MD, PhD, FRCR - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
|
Jul 18, 2023 |
|
Michael K. Wong, MD, PhD, FRCPC - Oncolytic Immunotherapies for Skin Cancer: Feasible and Practical Considerations
|
Jul 18, 2023 |
|
Johnny Mahlangu, MBBCH, MMed, FCPath - Redefining Balance in Hemophilia: Can We Restore Hemostasis by Inhibiting Anticoagulation?
|
Jul 17, 2023 |
|
Stephen Chia, MD, FRCPC - Exploring the Role of Immunotherapy in Triple-Negative Breast Cancer: A Turning Point for a Difficult-to-Treat Disease?
|
Jul 06, 2023 |
|
Barbara Melosky, MD, FRCPC - Navigating Recent Updates With Immunotherapy for Advanced NSCLC: Guidance to Optimize Treatment Decisions
|
Jun 28, 2023 |
|
D. Ross Camidge, MD, PhD - Mastering MET and cMET and Recognizing Their Role in Advanced NSCLC
|
Jun 27, 2023 |
|
Sara A. Hurvitz, MD, FACP - Clinical Case Challenge: Implementing ADCs Into Routine mTNBC Treatment Plans
|
Jun 27, 2023 |
|
Kevin Harrington, PhD, FRCR, FRCP - After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?
|
Jun 27, 2023 |
|
Aditya Bardia, MD, MPH - Keeping to Target in mTNBC: Optimising Outcomes With Antibody-Drug Conjugates in Practice
|
Jun 19, 2023 |
|
Sara A. Hurvitz, MD, FACP - Drug-Induced Interstitial Lung Disease and Breast Cancer: Knowing the Odds and Managing the Risk
|
Jun 19, 2023 |
|
Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations
|
Jun 19, 2023 |
|
Geoffrey Ku, MD - Here’s The Challenge! Overcoming Tumour Heterogeneity in Gastric/GEJ Cancers
|
Jun 13, 2023 |
|
Stephanie Snow, MD, FRCPC - First-Line Immunotherapy in Advanced Non-Small Cell Lung Cancer: Discussing a Game Plan
|
Jun 13, 2023 |
|
Nick Pavlakis, MBBS, PLD / Kohei Shitara, MD - The Evolution of Treatment for Advanced Gastric and Oesophageal Cancers: New Insights From Key Congresses
|
May 18, 2023 |
|
Julia Rotow, MD / Javier Cortés, MD - HER3-Targeted Therapies: How Might These Benefit Our Patients?
|
May 12, 2023 |
|
Hira Mian, MD, MSc, FRCPC - Moving the Needle in Relapsed Multiple Myeloma: Expert Insights to Address Key Questions in Patient Care
|
Apr 27, 2023 |
|
Laurie H. Sehn, MD, MPH - Clinical Update in the Treatment of Mantle Cell Lymphoma: The Evolving Evidence of BTK Inhibitors
|
Apr 27, 2023 |
|
John Storring, MD, CM, FRCPC - Current Therapeutic Strategies for Targeted Therapy Selection in De Novo Acute Myeloid Leukemia
|
Apr 24, 2023 |
|
Stefano Fanti, MD - Evolving Evidence of Radioligand Therapy in Metastatic Prostate Cancer: A 2023 Clinical Round-Up From Key Congresses
|
Apr 19, 2023 |
|
Emmanuella Guenova, MD, PhD - ‘T’ing Up Management of Mycosis Fungoides and Sézary Syndrome: Evaluating Blood Involvement and Its Impact on Patient Care
|
Apr 19, 2023 |
|
Kevin Harrington, PhD, FRCR, FRCP - When CPS is Between 1 and 19, How Would You Manage Recurrent/Metastatic SCCHN?
|
Apr 13, 2023 |
|
Jun-ichi Nishimura, MD, PhD / Austin Kulasekararaj, MD, FRCPath / Jeffrey Szer, MBBS, FRACP - Haemolysis in Paroxysmal Nocturnal Haemoglobinuria: Applying Assessment and Mitigation Strategies for Patients Receiving Complement Inhibitors
|
Apr 13, 2023 |
|
Thomas Powles, MBBS, MRCP, MD - Education, Collaboration and Communication: Aligning Patient and Clinical Priorities in Locally Advanced and Metastatic Urothelial Carcinoma
|
Apr 04, 2023 |
|
Vijay Ramaswamy, MD, PhD, FRCPC - Managing the Pediatric Patient With Plexiform Neurofibromas: The Case for Systemic Therapy
|
Apr 04, 2023 |
|
Alicia K. Morgans, MD, MPH - What Would You Do Next? Exploring Expert Perspectives on Clinical Cases and Compelling Questions in mHSPC and nmCRPC
|
Apr 04, 2023 |
|
Julie Stakiw, MD, FRCPC - Clinical Conundrums in CLL: When to Use Continuous Versus Fixed-Duration Treatment
|
Apr 03, 2023 |
|
Mary Frances McMullin, MD, FRCP, FRCPath - Managing Myelofibrosis: Can We Do More to Address Cytopenias, Reduce Transfusion Burden, and Improve Quality of Life?
|
Mar 29, 2023 |
|
Arndt Vogel, MD - Mobilising the Multidisciplinary Team: Collaborative Strategies to Improve Care in Early- to Intermediate-Stage HCC
|
Mar 28, 2023 |
|
John Papastergiou, BScPhm, PhDc - Human Papillomavirus Head and Neck Cancers: Improving Outcomes in Adults Through Vaccination
|
Mar 28, 2023 |
|
Silke Gillessen, MD - Optimal Treatment of mCRPC: What Is the Place of Radioligand Therapy?
|
Mar 23, 2023 |
|
Gerald Prager, MD - Don't Leave a Drug on the Table: Maximising Use and Benefits of Later-Line Treatments for Advanced Colorectal Cancer
|
Mar 23, 2023 |
|
Michael P. Chu, MD - Chimeric Antigen Receptor T Cells: A New Step in Improving Multiple Myeloma Management
|
Mar 23, 2023 |
|
Solange Peters, MD, PhD - Advancing Our Patient-Centered Approach to Care in ALK-Positive Metastatic Non-Small Cell Lung Cancer
|
Mar 23, 2023 |
|
Brandon M. Meyers, MSc, MD, FRCPC - Raising the Bar in Advanced Hepatocellular Carcinoma Care: Insights to Optimize First-Line Treatment
|
Mar 23, 2023 |
|
Tanios Bekaii-Saab, MD - Expert Perspectives on Treatment Sequencing in Advanced CRC: Keys to Reaching Later Lines of Therapy
|
Mar 23, 2023 |
|
Anna Tinker, BScH, MD, FRCPC - Getting on the Case of Advanced Endometrial Cancer: How Biomarkers May Inform Immunotherapy Treatment Decisions
|
Feb 24, 2023 |
|
Robert L. Coleman, MD - New Horizons in Cervical Cancer: Spotlight on Antibody-Drug Conjugates
|
Feb 08, 2023 |
|
Bruno Sangro, MD, PhD - A New Era in the Management of Advanced HCC: Sequencing Therapies for the Second-Line and Beyond
|
Jan 06, 2023 |
|
Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing
|
Jan 06, 2023 |
|
Susana Banerjee, MBBS, MA, PhD - When Patients With Advanced Endometrial Cancer Progress: Decisions in Treatment Initiation and Optimisation
|
Dec 28, 2022 |
|
Isabelle Ray-Coquard, MD, PhD - Turning Advanced Ovarian Cancer Into a Chronic Disease One Step at a Time
|
Dec 28, 2022 |
|
Alon Altman, MD, FRCSC - Aiming for Above Par Outcomes in Advanced Ovarian Cancer: The Role of Frontline Maintenance Therapy With PARP Inhibitors
|
Dec 22, 2022 |
|
Egbert F. Smit, MD, PhD - Novel Antigenic Targets for Antibody-Drug Conjugates in NSCLC
|
Dec 14, 2022 |
|
Stephanie Snow, MD, FRCPC - The Next Frontier in Precision Medicine: Understanding the Role of Liquid Biopsy in Cancer Care
|
Dec 07, 2022 |
|
Cynthia L. Toze, MD, MHSc, FRCPC - Real-World Evidence of BTK Inhibitors in CLL: Maximizing Therapy Benefits While Minimizing Safety Concerns
|
Dec 07, 2022 |
|
Kjeld Schmiegelow, MD, DMSci - Asparaginase Therapy in Children and Young Adults With ALL/LBL: When You Need to Switch
|
Dec 05, 2022 |
|
Christopher Venner, MD - Insights to Guide Early Recognition and Linkage to Care in AL Amyloidosis: An Expert Discussion
|
Nov 18, 2022 |
|
Paolo Antonio Ascierto, MD - Emerging Data on Adjuvant Immunotherapy for Resected Melanoma: What Changes?
|
Nov 17, 2022 |
|
Mohamad Mohty, MD, PhD - Veno-Occlusive Disease: Who to Treat, How to Treat, When to Treat
|
Nov 01, 2022 |
|
Noemi Reguart, MD, PhD - Evaluating the Evidence for Emerging Therapies in NSCLC: Highlights From Summer/Fall 2022
|
Oct 27, 2022 |
|
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC
|
Oct 04, 2022 |
|
Expert Guidance for Improving Outcomes in Advanced NSCLC: Utilising ADCs in Practice
|
Oct 03, 2022 |
|
The Case for Better Care in Newly Diagnosed Multiple Myeloma: How Can We Improve Outcomes in Challenging Clinical Scenarios?
|
Sep 30, 2022 |
|
Right Drug, Right Patient, Right Time: Cases in “Precisionalised” Treatment of Advanced NSCLC
|
Sep 29, 2022 |
|
Managing Cytopenic Myelofibrosis: New and Emerging Therapies and Who May Benefit
|
Sep 29, 2022 |
|
Hot Topics and Controversies in Adjuvant Therapy for Early-Stage, EGFR-Mutant NSCLC
|
Sep 20, 2022 |
|
Reassessing Management of Advanced and Recurrent Endometrial Cancer: The Value of Multidisciplinary and Overall Care
|
Sep 07, 2022 |
|
Adjuvant Therapy for Patients With Resected Melanoma: Finessing Care to Improve Survival in High-Risk Patients
|
Sep 07, 2022 |
|
Personalised Management of Newly Diagnosed Secondary Acute Myeloid Leukaemia: Determining Factors That Impact Treatment Decisions
|
Sep 07, 2022 |
|
Strategies to Guide Treatment Selection in Relapsed/Refractory AML: An Expert Discussion
|
Aug 29, 2022 |
|
Starting Strong at First Relapse in Multiple Myeloma: Insights to Guide Treatment Selection in Lenalidomide-Refractory Patients
|
Aug 29, 2022 |
|
Question Time: Applying New Therapies for the Management of mTNBC
|
Aug 29, 2022 |
|
New Biomarkers, New Targets in Advanced NSCLC
|
Aug 17, 2022 |
|
Addressing the Triple Challenge of Myelofibrosis: Symptoms, Splenomegaly, and Cytopenias
|
Aug 01, 2022 |
|
IAP Antagonists in Oncology: What Do We Know?
|
Jul 25, 2022 |
|
The Next Frontier in Immunotherapy for Multiple Myeloma: What Will BCMA Targeting Mean for Our Relapsed/Refractory Patients?
|
Jul 15, 2022 |
|
Practical Guidance for Identifying and Managing Patients With Advanced MET Exon 14-Skipping NSCLC
|
Jul 11, 2022 |
|
Insights on the Increasing Impact of Emerging Therapies in NSCLC: Highlights From Spring 2022
|
Jun 30, 2022 |
|
Making Informed Treatment Choices for the Elderly Patient With CLL: A Look at the Evidence
|
Jun 07, 2022 |
|
Gastric Cancer in the Crosshairs: The Evolving Role of Biomarkers and Targeted Therapy in Managing Advanced Gastric Cancer
|
Jun 03, 2022 |
|
Managing the Nuances of Paroxysmal Nocturnal Haemoglobinuria: Practical Strategies for Patients Receiving Complement Inhibitors
|
May 26, 2022 |
|
Managing Thrombosis in Cancer: A Double Debacle and Then Add COVID
|
May 18, 2022 |
|
‘B’ Vigilant: HCC Surveillance Protocols in Patients With Chronic Hepatitis B
|
May 16, 2022 |
|
Personalising Management of Advanced RCC: How I Treat
|
May 16, 2022 |
|
Immunotherapeutic Approaches in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Insights From the Real World
|
May 05, 2022 |
|
Treatment of Metastatic Triple-Negative Breast Cancer: Progress and Perspective
|
May 03, 2022 |
|
A Clinical Conversation on Metastatic Hormone-Sensitive Prostate Cancer: Intensifying Therapy Earlier in the Disease Course
|
Apr 26, 2022 |
|
Complex Cases of Comorbidities in Patients With HCV
|
Apr 21, 2022 |
|
"Defining the Diagnosis and Management of Pyruvate Kinase Deficiency"
|
Apr 20, 2022 |
|
Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma in the Era of Monoclonal Antibodies: Applying the Evidence to Patient Care
|
Apr 20, 2022 |
|
Immunotherapy Combinations for First-Line Advanced NSCLC Treatment: Clinical Insights on Current and Emerging Options
|
Mar 29, 2022 |
|
Transforming Care With Adjuvant Immunotherapy in Muscle-Invasive Urothelial Carcinoma
|
Mar 29, 2022 |
|
Immunotherapy in Advanced Endometrial Cancer: Challenges and Opportunities
|
Mar 29, 2022 |
|
Applying Revised Treatment Guidelines for Advanced Hepatocellular Carcinoma: Considerations in Real-Life Practice
|
Mar 01, 2022 |
|
More Than Skin Deep: Systemic Therapy for Advanced Cutaneous Squamous Cell Carcinoma
|
Mar 01, 2022 |
|
Upping the Ante: Considering Monoclonal Antibodies in Transplant Ineligible Newly Diagnosed Multiple Myeloma
|
Mar 01, 2022 |
|
The Place of Radiopharmaceuticals in an Evolving Treatment Landscape: Addressing Perceptions With Clinical Evidence to Optimise Outcomes in Men With Metastatic Prostate Cancer
|
Feb 28, 2022 |